[1] 叶辉, 顾龙君. 大剂量甲氨蝶呤治疗急性淋巴细胞白血病的研究进展. 中国血液学杂志, 1999, 20(2): 110.[2] 韩月芹, 阵力军. 氨甲蝶呤的副作用——粘膜炎发生与修复机制的研究进展. 中国小儿血液, 2003, 8(5): 231-236.[3] Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Che, 1985, 260(17): 9720-9726.[4] Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC, Pui CH, Downing JR, Relling MV, Evans WE. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest, 2005, 115(1): 110-117.[5] Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, Crist WM, Pui CH, and Evans WE. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest, 1994, 94(5): 1996-2001.[6] Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 1990, 348(6299): 334-336.[7] Zhang J, Ma C, Han X, DurrinL K, Sun Y. The bcl-2 major breakpoint region (mbr) possesses transcriptional regulatory function. Gene, 2006, 379(S1): 127-131.[8] Ma C, Zhang J, Durrin LK, Lv J, Zhu D, Han X, Sun Y. The BCL2 major breakpoint region (mbr) regulates gene expression. Oncogene, 2007, 26(18): 2649-2657.[9] Leclerc GJ, York TA, Hsieh-Kinser T, Barredo JC. Molecular basis for decreased folypoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line. Leuk Res, 2007, 31(3): 293-299.[10] Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood, 2009, 113(18): 4362-4369.[11] 李道静, 何晓东, 孙余婕, 凡任芝, 许维东, 孙利, 张永娟, 张白银, 沈佐君. 氨甲蝶呤对映体获得性耐药A549细胞株二氢叶酸还原酶基因表达分析. 临床检验杂志, 2011, 29(3): 219-221.[12] Sohn KJ, Smirnakis F, Moskovitz DN, Novakovic P, Yates Z, Lucock M, Croxford R, Kim YI. Effects of folylpoly-glutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. Gut, 2004, 53(12): 1825-1831. |